Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- The primary endpoint will be a comparison of intimal thickness in the coronary artery by Optical Coherence Tomography with presence or absence of donor specific antibodies.
Study Overview
Brief Summary
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation. CAV has been associated with a variety of traditional risk factors for atherosclerosis; however, immune mediated injury from development of de-novo donor-specific antibodies after transplantation also likely plays an important role. Similar to the progression of traditional atherosclerosis, it is likely that endothelial dysfunction is the precursor to the development of intimal thickening and CAV.
The investigators hypothesize that coronary allograft vasculopathy after heart transplantation as defined by progressive neointimal hyperplasia is preceded by endothelial dysfunction, which in turn is at least partly mediated by donor specific antibodies.
The investigators are proposing a prospective study in humans to test the above hypothesis and further mechanistically understand how CAV progresses. In this study the investigators will test for coronary endothelial function by infusing acetylcholine into the coronary artery and measure intimal hyperplasia by optical coherence tomography (OCT) and compare findings in patients with and without donor specific antibodies.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects who are 1 year post heart transplantation
- •Subjects will include both male and females
- •Be at least 18 years of age
Exclusion Criteria
- •Known coronary artery disease after transplantation
- •Evidence of strong or moderate antibodies already present at the time of the transplant
- •Severe renal dysfunction defined as creatinine clearance of <30 or on hemodialysis.
- •3 or more episodes of acute cellular rejection
- •Females who are pregnant
- •Patients requiring endomyocardial biopsy at the time of catheterization
- •Patients unable to tolerate heparin or systemic anticoagulation
- •History of multi-organ transplant
- •Patients unable to give consent
Arms & Interventions
Single arm
All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
Intervention: Optical Coherence Tomography (Device)
Single arm
All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
Intervention: Acetylcholine (Drug)
Single arm
All subjects will undergo a Brachial Artery Flow Medicated Dilation prior to heart catheterization. After routine heart catheterization, images of their coronary artery will be recorded by Optical Coherence Tomography (OCT) during infusion of Acetylcholine.
Intervention: Brachial Artery Flow Mediated Dilation (Procedure)
Outcomes
Primary Outcomes
The primary endpoint will be a comparison of intimal thickness in the coronary artery by Optical Coherence Tomography with presence or absence of donor specific antibodies.
Time Frame: baseline (year 1 post transplant) and annually for 2 years
Secondary Outcomes
- Natural progression of coronary allograft vasculopathy over first 2 years after transplantation(baseline (year 1 post transplant) and annually for 2 years)
- Assessment of epicardial coronary endothelial function by measuring change in vessel size in response to acetylcholine and how this compares to peripheral endothelial function.(baseline (year 1 post transplant) and annually for 2 years)
- Prospectively determine the association of HLA and non-HLA donor specific antibodies that activate complement with endothelial dysfunction and intimal thickening.(baseline (year 1 post transplant) and annually for 2 years)
- Comparison of endothelial function in the coronary artery with presence or absence of donor specific antibodies.(baseline (year 1 post transplant) and annually for 2 years)
- Plaque characterization in coronary artery by OCT(baseline (year 1 post transplant) and annually for 2 years)
- Gene expression of white blood cells by microRNA and how this relates to endothelial function and intimal thickness.(baseline (year 1 post transplant) and annually for 2 years)
Investigators
Catalin Toma, MD
Assistant Professor
University of Pittsburgh